Partial
Partially Aligned
Patient Risk:
Medium
Summary
Many statements about pharmacokinetic interaction with strong CYP3A4 inhibitors and increased myopathy/rhabdomyolysis risk are broadly consistent with the label, but multiple claims about antidepressants (SSRIs/SNRIs specifically, serotonin syndrome, and bleeding) are not supported by the provided FDA label text.
Category Scores
Accurate Statements
Lipitor can inhibit cytochrome P450 enzymes that metabolize many medications, including antidepressants.
Partially supported/consistent in concept: label states LIPITOR is metabolized by CYP3A4 and that strong CYP3A4 inhibitors can increase atorvastatin plasma concentrations (7.1). However, the claim is broad and not specifically about antidepressants.
Lipitor can increase the risk of side effects.
The label supports increased risk of myopathy/rhabdomyolysis and increased plasma concentrations/potentiation of effects with strong CYP3A4 inhibitors (7.1) and increased risk of skeletal muscle effects (5.1). It does not enumerate “side effects” generally for antidepressant interactions.
The muscle damage risk described includes rhabdomyolysis.
Label states rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with LIPITOR and other drugs in this class (5.1).
Unsupported Statements
When Lipitor is taken with certain antidepressants such as SSRIs and SNRIs, it can increase the risk of serotonin syndrome.
No serotonin syndrome/serotonin syndrome risk with antidepressants is described in the provided label sections.
Serotonin syndrome is described as a potentially life-threatening condition caused by excessive serotonin levels.
No such definition/description appears in the provided label text.
Fluoxetine (Prozac) can increase the risk of bleeding.
No bleeding risk with fluoxetine (or antidepressants) appears in the provided label text.
Fluoxetine can interact with Lipitor to increase the risk of muscle damage.
No fluoxetine-specific drug interaction is described in the provided label text.
Sertraline (Zoloft) can interact with Lipitor to increase the risk of bleeding.
No bleeding risk with sertraline (or antidepressants) appears in the provided label text.
Sertraline can interact with Lipitor to increase the risk of muscle damage.
No sertraline-specific interaction is described in the provided label text.
Paroxetine (Paxil) can interact with Lipitor to increase the risk of bleeding.
No bleeding risk with paroxetine (or antidepressants) appears in the provided label text.
Paroxetine can interact with Lipitor to increase the risk of muscle damage.
No paroxetine-specific interaction is described in the provided label text.
Venlafaxine (Effexor) can interact with Lipitor to increase the risk of bleeding.
No bleeding risk with venlafaxine (or antidepressants) appears in the provided label text.
Venlafaxine can interact with Lipitor to increase the risk of muscle damage.
No venlafaxine-specific interaction is described in the provided label text.
Duloxetine (Cymbalta) can interact with Lipitor to increase the risk of bleeding.
No bleeding risk with duloxetine (or antidepressants) appears in the provided label text.
Duloxetine can interact with Lipitor to increase the risk of muscle damage.
No duloxetine-specific interaction is described in the provided label text.
Lipitor can increase the risk of bleeding when taken with certain antidepressants such as SSRIs and SNRIs.
No bleeding risk with SSRIs/SNRIs is described in the provided label text.
Lipitor can interact with antidepressants to increase the risk of bleeding.
No antidepressant-related bleeding interaction is described in the provided label text.
Lipitor can increase the risk of serotonin syndrome when taken with certain antidepressants such as SSRIs and SNRIs.
No antidepressant-related serotonin syndrome interaction is described in the provided label text.
Lipitor can interact with antidepressants to increase the risk of liver damage.
The label discusses liver enzyme abnormalities generally and monitoring, but it does not describe an antidepressant-specific interaction increasing liver damage in the provided text.
Lipitor antidepressant interactions can increase the risk of liver damage.
No antidepressant-specific interaction increasing liver damage is described in the provided label text.
Avoid taking Lipitor with certain antidepressants such as SSRIs and SNRIs unless prescribed by a doctor.
The provided label does not state an avoidance/contraindication guidance for SSRIs/SNRIs.
The risk of bleeding with Lipitor and antidepressants is described as a significant concern.
No such bleeding concern regarding antidepressants is described in the provided label text.
Contradictions
Important Omissions
When Lipitor is taken with strong CYP3A4 inhibitors, label-based cautions include that such coadministration can increase atorvastatin plasma concentrations and that caution is used when the Lipitor dose exceeds 20 mg for certain interacting drugs (e.g., clarithromycin, HIV protease inhibitors, itraconazole), and caution/monitoring for skeletal muscle effects with interacting drugs.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Unsupported claims about serotonin syndrome and bleeding with antidepressants could mislead risk assessment. Supported label content focuses on increased myopathy/rhabdomyolysis risk with certain interacting drugs (e.g., strong CYP3A4 inhibitors) and liver function test monitoring.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple antidepressant-specific interaction claims (SSRIs/SNRIs; serotonin syndrome; bleeding; specific drugs) are not supported by the provided Lipitor label sections.
Suggested Improvement
Restrict interaction statements to those described in the label text provided (e.g., increased myopathy/rhabdomyolysis risk with cyclosporine/fibric acid derivatives/niacin/strong CYP3A4 inhibitors and related monitoring/caution dose guidance). Remove unsupported serotonin syndrome, bleeding, and antidepressant-specific interaction claims unless supported by additional label sections not provided.